KLRK1 and chronic myelogenous leukemia, BCR-ABL1 positive: Regarding the activating receptor NKG2D, we found a significant decrease in the MFI of NKG2D on CD56bright NK cells in old CML patients compared with old healthy donors, and a decrease with age in CML patients (Figure 1B).